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Abstract
Purpose Randomized controlled trials
have shown the efﬁcacy of atropine for
progressive myopia, and this treatment
has become the preferred pattern for this
condition in Taiwan. This study explores
the effectiveness of atropine 0.5% treatment
for progressive high myopia and adherence
to therapy in a non-Asian country.
Methods An effectiveness study was
performed in Rotterdam, the Netherlands.
Overall 77 children (mean age 10.3 years± 2.3),
of European (n=53), Asian (n=18), and
African (n=6) descent with progressive
myopia were prescribed atropine 0.5% eye
drops daily. Both parents and children ﬁlled
in a questionnaire regarding adverse events
and adherence to therapy. A standardized eye
examination including cycloplegic refraction
and axial length was performed at baseline and
1, 4, and 12months after initiation of therapy.
Results Mean spherical equivalent at baseline
was −6.6D (±3.3). The majority (60/77, 78%) of
children adhered to atropine treatment for
12months; 11 of the 17 children who
discontinued therapy did so within 1month
after the start of therapy. The most prominent
reported adverse events were photophobia
(72%), followed by reading problems (38%),
and headaches (22%). The progression rate of
spherical equivalent before treatment (−1.0D/
year±0.7) diminished substantially during
treatment (−0.1D/year±0.7) compared to those
who ceased therapy (−0.5D/year±0.6; P=0.03).
Conclusions Despite the relatively high
occurrence of adverse events, our study
shows that atropine can be an effective and
sustainable treatment for progressive high
myopia in Europeans.
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Introduction
Worldwide, the prevalence of myopia has been
rising dramatically, and it is estimated that 2.5
billion people will be affected by myopia by
2020.1 South-East Asia is now facing a myopia
frequency up to 95.5% in young academics,2,3
but a rising trend has also been observed in recent
European studies.4 The high rise also includes the
prevalence of high myopia (o− 6D; axial length
≥ 26 mm), which in particular is associated with
severe complications, such as myopic macular
degeneration, retinal detachment, and glaucoma.2
The absolute risk of severe visual impairment is
30% in individuals with axial length of 26 mm,
and increases up to 95% in those with an axial
length of 30 mm or more.5,6
These dramatic ﬁgures create the need for
effective counteractions. Current treatment
options for progressive myopia can be categ-
orized in conservative and pharmacological
interventions.7 The effects of the conservative
regimens, except for the orthokeratology, are
relatively small.8 Pharmacological intervention
has a much higher efﬁcacy, in particular treatment
with topically applied atropine eye drops.9
Atropine, a non-selective muscarinic receptor
antagonist (M-antagonist), is the most studied
pharmacological agent for the intervention of
progressive myopia.10 In animals, topical atropine
showed an inhibitory effect on lens-induced
and -deprived myopia.11 In humans, the use
of atropine to reduce myopic progression was
published decades ago,12 but it was not until the
ATOM study performed their large randomized
clinical trial in 400 children of Asian ethnicity
that atropine was acknowledged as an effective
treatment for myopia progression.10 This 2-year
study found 75% reduction of myopic progress-
ion with atropine 1%, and did not report
serious side effects. A systematic Cochrane
review on atropine studies reported that myopia
progression can be reduced by 0.80–1.0D after
a year of treatment of atropine 0.5 and 1%,
respectively.7
Atropine is the preferred practice pattern for
progressive myopia in Taiwan.13 As early as
the year 2000, the Ophthalmological Society of
Taiwan advised to use atropine to slow down
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myopia progression.13 This treatment is prescribed to
nearly 50% of Taiwanese children with progressive
myopia.13 Although topical use of atropine is known
to cause photophobia and accommodation lag, these
adverse events do not appear to hamper its implementa-
tion in Taiwanese children. By contrast, the lighter iris color
in Europeans is generally considered as a barrier for its
use in the Western world.14 Moreover, some studies have
suggested that atropine is less effective in persons of non-
Asian descent.15
The aim of this study was to investigate the effect
of atropine for progressive myopia under ‘real-world’
conditions in a non-Asian country. We compared rates
of myopia progression in consecutive children before and
after therapy, assessed common complaints, evaluated
reasons for discontinuation, and developed practice
guidelines.
Methods
Study design, population, and intervention
The design was an effectiveness study, and was
prospective and clinic-based. The setting was Erasmus
Medical Center and Sophia Children’s Hospital in
Rotterdam, the Netherlands, and all consecutive children
younger than 18 years of age presenting with progressive
myopia were eligible for the study. Inclusion criteria were
spherical equivalent (SE) ≤− 3D and SE progression rate
≥ 1D/year under cycloplegic conditions; exclusion criteria
were myopia related to retinal dystrophies or collagen
syndromes, and developmental disorders. Eligible children
and parents received a patient information leaﬂet followed
by oral consultation. After providing written informed
parental consent (parents or legal guardians for children
≤ 12 years; also including children for ages 12+ years),
participants received a prescription of atropine eye drops
0.5% (FNA Dutch pharmacists). Both eyes were treated
by atropine eye drops once daily before bedtime by the
parent. The study and protocol adhered to the tenets of
the Declaration of Helsinki, and were approved by the
Medical Ethics Committee of the Erasmus Medical Centre.
Eye examination
A standardized ophthalmological examination was
performed at baseline, 1 month, 4 months, and 12 months
after initiation of atropine treatment. Best corrected
visual acuity was performed with a decimal equivalent
(minutes) visual acuity chart at 6 m distance. Binocular
reading visual acuity was performed with the LogMAR-
based Dutch Radner reading chart at 25 or 40 cm.16
Pupil size was measured with Richmond Products Clear
Pupilometer (Albuquerque, NM, USA). At baseline, full
cycloplegia was obtained 45 min after administration
of 1% cyclopentolate eye drops. At follow up, cycloplegia
was already present at examination due to the use of
atropine; this was conﬁrmed by the investigators with
dynamic retinoscopy, and was therefore considered a
measure of compliance. Subsequently, the refractive
error was measured with a Topcon auto refractor
KR8900 (Topcon, Tokyo, Japan); in younger children with
a Nikon Retinomax 2 auto refractor (Nikon, Tokyo,
Japan), and in very young or uncooperative children
refractive error was determined by an experienced
orthoptist (JRP) performing retinoscopy with a Heine beta
200 retinoscope (Heine Optotechnik, Herrsching,
Germany) and lenses according to standard protocols.
The same devices were used throughout the study period.
Spherical equivalent was calculated using the standard
formula: (SE= sphere+1/2 cylinder). Axial length was
measured with the IOL Master 500 (Carl Zeiss MEDITEC
IOL-master, Jena, Germany) at each visit.
Risk factors and adverse events
At baseline, and after 4 and 12months after the start
of atropine, as well as 1 month after cessation of therapy,
parents and children ﬁlled in a questionnaire evaluating
adverse events. The questionnaires were ﬁlled in
independent of each other at different locations; children
o8 years of age received help of the investigator. The
questions for the parents concerned risk factors for myopia,
adverse events, and adherence to therapy; the questions for
the children concerned only the latter two, and were
simpliﬁed versions of the same questions for parents.
Statistical analysis
All data were entered into a database as nominal or ordinal
variables. Proportions were calculated, and data before
and after start of atropine treatment were compared
with Fisher’s exact test. Biometric measures of the eye
were analyzed using Mann–Whitney U non-parametric
test. Throughout the study, P= 0.05 was used as border
of signiﬁcance.
The annual progression rate before treatment was
calculated by subtracting the SE at baseline from the
SE estimated 1 year before treatment for each participant.
We calculated the progression rate during treatment by
subtracting the SE at 1 year follow up (−6.8D± 3.6) from
the SE estimated at baseline (−6.7D± 3.6). The rate was
analyzed with Wilcoxon signed ranks test to identify
short term differences during the 1 year of treatment.
Risk of adverse events and adherence to therapy
were estimated using logistic and linear regression
analysis. Multivariate logistic regression analysis was
used to determine the risk of discontinuation of therapy
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with age, gender, baseline SE, and ethnicity in the
model. All statistical tests were performed by using
IBM SPSS Statistics for Windows, Version 21.0. (IBM
Corp., Armonk, NY, USA).
Results
From March 2011 to July 2013, a total of 84 consecutive
progressive myopic children visited our clinic and were
considered eligible for this study. Of these, 78 (92.9%)
consented to participation and 6 (7.1%) refused. Of those
consented, 1 (1.3%) child was lost to follow up during the
course of the study. The remaining 77 children completed
12 months of follow up.
Demographics of the study population are summarized
in Table 1. Gender was evenly distributed; the mean age
was 10.3 (±3.2) years, and two-third of the children had
European ancestry. The mean refractive error 1.1 (±0.6)
year before treatment was −5.6D (±3.9). At baseline,
mean refractive error was − 6.63D (±3.31), resulting in a
mean progression rate of − 1.0 (0.7). Half (50.6%) of the
children were already highly myopic (SE 4− 6D, ranging
from − 6.13D to − 18.63D). Mean pupil diameter before
treatment was 4.4 mm (95% CI: 3.3–5.5). The majority
(84.7%) reported at least one myopic parent. Five children
had been adopted, and had no information on the
refractive error of the biological parents.
Of the 77 children, 60 (78%) adhered to therapy for the
complete follow up of 1 year. Annual progression rates
showed an advantage for the children who stayed on
therapy (0.1D/year) vs the children who discontinued
therapy (0.5D/year) (P 0.03) (Table 2). Mean change in SE
from baseline to 1 year before and during the year of
treatment is presented in Figure 1. The SE difference from
baseline to the ﬁrst month of treatment appeared to
improve by 0.19D (±0.41) compared to baseline, but this
temporary inverse progression of myopia was not
sustained thereafter. The SE difference from baseline to 6
and 12months was signiﬁcantly lower than before therapy
and approached almost 0 (0.12 and −0.05D, Po0.01).
Age modiﬁed the treatment effect signiﬁcantly
(P= 0.01): children younger than 9 years of age had
the lowest treatment effect (annual progression rate
− 0.49D, CI: − 0.90 to − 0.08); 9–12 year olds had more
effect (annual progression rate − 0.06D, CI: − 0.47 to
+0.35), and older children had the highest treatment
effect (annual progression rate 0.02D, CI: − 0.27 to +0.3).
Ethnicity (P= 0.58) nor gender (P= 0.76) signiﬁcantly
inﬂuenced annual progression rate during treatment.
More than half (36/60; 60%) of the children who
adhered to therapy did not report any skips in
therapy administration. None showed more than 0.5D
accommodation on dynamic retinoscopy. The mean
pupil diameter was 7.0 mm (±0.63) during the follow
up visits. The most frequent reason for skips was
forgetfulness. Overall 61.7% of children who commenced
with atropine, 17 stopped treatment, of whom 11 (64.7%)
within the ﬁrst 4 weeks (Table 3). Adverse events were
reported as the primary reason (82.4%). The frequency
of dropouts was higher in those aged 12 years and over
(13.0% in age o12 years vs 44.4% in 12+ years; Po0.01).
The questionnaires addressing treatment response and
adverse events showed remarkable similarity between
parents and their children, although children reported
complaints at slightly higher frequencies. Adverse events
occurred often, 63 (82.9%) reported these by both parents
and children. Photophobia (72.4%) and reading problems
(37.7%) were reported most frequently; 22.4% reported
headaches; and systemic ﬂushes occurred only in a
Table 1 Distribution of demographics and clinical measures of
study participants with progressive myopia
Characteristics at baseline
Patients, n 77
Gender, n (%)
Male 39/77 (50.6%)
Female 38/77 (49.4%)
Mean age in years (SD), (range) 10.34 (±3.21) (2.7–16.8)
Mean SE in D (SD) − 6.63 (±3.31)
Mean age in groups, n (%)
o9 years 26/77 (33.8%)
9–11 years 48/77 (32.5%)
12–16 years 22/77 (33.8%)
Ethnicitya
European 53/77 (68.8%)
Asian 18/77 (23.4%)
African 6/77 (7.8%)
Age started readinga,b, n (%)
o5 years 26/72 (33.8%)
5 years 20/72 (26.0%)
6 years 20/72 (26.0%)
47 years 4/72 (5.2%)
Reading habitsa,c, n (%)
Never 5/70 (7.1%)
o5 h/week 33/70 (42.9%)
5–15 h/week 23/70 (29.9%)
415 h/week 7/70 (9.1%)
Outdoor activitiesa, n (%)
o1 h/day 23/77 (29.9%)
1–3 h/day 45/77 (58.4%)
43 h/day 9/77 (11.7%)
Parental presence of myopia, nc (%) 57/77 (74.0%)
aObtained by questionnaire.
bOnly current readers could be included for this question.
cParents of seven children were not able to answer this question: n= 5 no
reading skills, n= 2 insufﬁcient reading skills (at time of questionnaire).
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minority. Those who discontinued therapy reported reading
problems signiﬁcantly more often than those who
maintained therapy (12/15 (80%) vs 13/54 (24.1%), Po0.01)
(Table 4). Other reported events were rare: pain in the eye,
irritated eyes, overﬂow of tears, trouble with depth
perception, cosmetically disﬁguring pupils, and an
unpleasant taste in mouth (all reported only in one patient).
Discussion
Our study shows that atropine 0.5% can be an effective
treatment for progressive myopia in a European setting.
The mean progression rate before the year of intervention
was − 1.0D (±0.7)/year. Atropine 0.5% reduced this
to − 0.1D (±0.7)/year during treatment. Despite a high
frequency of adverse events, most children managed
to prolong therapy for the entire study period. Those
children who prolonged therapy had a signiﬁcant
advantage over those who stopped (P= 0.03). The effect
of treatment was dependent on age, and was most
prominent in teenagers. Although not powered to test
for ethnicity and gender, these did not appear to inﬂuence
treatment outcome in our study.
We deliberately chose a pragmatic study design to
make a translation from ﬁndings of efﬁcacy studies to
daily practice. Numerous studies including randomized
controlled trials have reported on the efﬁcacy of atropine
treatment for progressive myopia. An effectiveness study
such as ours more closely reﬂects daily practice as it
consisted of a heterogeneous patient population with a
large range in refractive errors and age, and inclusion of
multiple ethnicities. Other strengths of our study are the
Table 2 Spherical equivalent and axial length over time in children who prolonged and ceased atropine therapy
Prolonged therapy, N= 60 (77.9%) Ceased therapy, N= 17 (22.1%) P value
Age (year) at baseline
study, mean (± )
10.0 (3.2) 11.4 (2.8) 0.09
Spherical equivalent (SE) SE (D) SE (D)
12 months before treatment −5.6 (3.9) − 5.7 (3.1) 0.85
Start treatment − 6.7 (3.6) − 6.5 (2.8) 0.80
12 months after start treatment − 6.8 (3.6) − 7.1 (2.6) 0.55
Annual myopic progression rate (PR)
Pre-treatment to start treatment (D/year) − 1.0 (0.7) − 0.9 (0.5) 0.33
12 months after start treatment (D/year) − 0.1 (0.7) − 0.5 (0.6) 0.03
Axial length (AL)
Start treatment (mm) 25.19 (0.97) 25.46 (1.21) 0.82
12 months after start treatment (mm) 25.54 (1.35) 25.83 (1.4) 0.66
Annual AL progression rate (PR)
Pre- treatment to start treatment (mm/year) n.a. n.a.
12 months after start treatment (mm/year) − 0.11 (0.20) − 0.12 (0.14) 0.73
The bold value represents signiﬁcant difference (Pr0.05) between those who maintained therapy and those who did not.
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Figure 1 Mean change in SE from baseline 1 year before and during the year of treatment. Error bars present 95% CI.
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standardized measurements of cycloplegic refraction, and
the cross evaluation of parents and children by question-
naire to improve the validity of data on adherence and
adverse events. Among the limitations are the relatively
short follow up, and the absence of a ﬂexible dosing
regimen which would have allowed tailored therapy
for each subject.
Higher concentration atropine eye drops are known for
their frequent occurrence of adverse events, and our study
conﬁrms this. Most commonly reported adverse events
were photophobia and reading problems. Headaches
occurred in approximately one-ﬁfth of the patients, but
were reported to be mild and transient. Flushes of the
cheeks were observed in only three children, but were
not a reason to discontinue therapy.
Cessation of therapy most often occurred shortly
after the start of therapy. Children who managed to
adhere to therapy for 4 weeks were more likely to prolong
therapy thereafter. Most important startup difﬁculties
were adaptation to the bright light and coping with
reading problems. Following from this observation, we
therefore recommend to prescribe transitional multifocal
glasses at the initiation of therapy. We also experienced
that comprehensive instruction of the parent and child
through information brochures and oral clariﬁcation
was greatly appreciated, and may improve motivation.
After cessation of therapy, a rebound, or catch-up, growth
spurt has been described.17 Tong et al18 found that the
positive effect of atropine lasted up to 3 years before
being caught up by the rebound effect. Maintaining
therapy for a longer period of time and tapering with
lower concentrations after achieving stability are
suggested to prevent this rebound effect.19
Atropine is the standard of care for myopia progression
in Taiwan.13 The reasons for not prescribing atropine
for progressive myopia in western countries is as yet
unclear. One reason may be the report of a higher efﬁcacy
of treatment in Asians than in Europeans. Although our
power to study differences herein was low, our study
could not conﬁrm any differences between ethnicities.
Another reason may be fear for serious and irreversible
complications after prolonged use, but this is not
substantiated by literature. Long-term effects of atropine
treatment have been investigated in both animal as well
as human studies,20,21 and photochemical damage to the
retina due to enlarged pupil for a longer period of time
under daylight conditions has not been reported.22,23
Therefore, daily atropine appears to be a safe treatment,
even if used for several years.12,24,25
A remarkable ﬁnding was that the refractive error
showed a hyperopic shift after 4 weeks, which disappeared
after 4 months. This effect could be caused by the stronger
cycloplegic effect of atropine over classical cycloplegic
agents used in the clinic, such as cyclogyl.26 The reduction
in refractive error could also be the result of a temporary
thickening of the choroid, a phenomenon observed in
animal studies.27
How atropine manages to interfere with myopia
progression has not been well established, neither is
Table 3 Adherence to atropine therapy and time and reasons
for ceasing
Parent report Child report
Maintained therapy 60/77 (77.9%) 60/77 (77.9%)
Adherence
Full adherence 39/60 (65.0%) 36/60 (60%)
Adherence 46×/weeks 17/60 (28.3%) 18/60 (30%)
Adherence 4–6×/weeks 3/60 (5.0%) 5/60 (8.3%)
Adherence o4×/weeks 1/60 (1.7%) 1/60 (1.7%)
Reason non-adherence
Forgotten 37/60 (61.7%) 28/60 (46.7%)
Adverse events 2/60 (3.3%) 3/60 (5%)
Application eye drops 1/60 (1.7%) 2/60 (3.3%)
Ceased therapy 17/77 (22.1%) 17/77 (22.1%)
Duration of therapy before ceasing
o1 weeks 7/17 (41.2%) 7/17 (41.2%)
1–4 weeks 4/17 (23.5%) 4/17 (23.5%)
44 weeks 6/17 (35.3%) 6/17 (35.3%)
Reason for ceasing
Adverse events 14/17 (82.4%) 14/17 (82.4%)
Application eye drops 1/17 (5.9%) 1/17 (5.9%)
Other 2/17 (11.8%) 2/17 (11.8%)
Table 4 Adverse events in children who maintained and ceased therapy
Maintained therapy, n (%) Ceaseda therapy, n (%)
Parent report Child report Parent report Child report
No 11/60 (18.3%) 11/60 (18.3%) 2/16 (12.5%) 2/16 (12.5%)
Photophobia 36/60 (60%) 42/60 (70.0%) 12/16 (75.0%) 13/16 (81.2%)
Reading problemsb,c 13/54 (24.1%) 14/54 (25.9%) 12/15 (80.0%) 12/15 (80.0%)
Headache 4/60 (6.7%) 13/60 (21.7%) 5/16 (31.2%) 4/16 (25.0%)
Systemic (ﬂushes) 2/60 (3.3%) 2/60 (3.3%) 1/16 (6.2%) 1/16 (6.2%)
Infections (conjunctivitis, blepharitis) 2/60 (3.3%) 1/60 (1.7%) 0/16 (0%) 0/16 (0%)
Other 6/60 (10.0%) 4/60 (6.7%) 2/16 (12.5%) 3/16 (18.8%)
aA total of 16/17 could be included, only 1 participant did not return the questionnaire.
bOnly in children who started to read, n= 54 vs n= 15.
cSigniﬁcant difference (P≤0.01) between those who maintained therapy and those who did not.
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there agreement on the site of action.28 This may be
the retina, because amacrine cells can express muscarinic
receptors on their cell membrane.29 Binding of atropine
to the muscarinic receptors of amacrine cells has been
hypothesized to increase the release of dopamine,
which ﬁts well with the view that dopamine is an
inhibitory chemical mediator for eye growth.30
Reduction of ɣ-aminobutyric acid levels is also a possible
mechanism, as this neurotransmitter was shown to be
downregulated following atropine treatment in myopia-
induced mice.31 Other explanations include an effect of
atropine via the sclera. Scleral ﬁbroblast cells carry all ﬁve
muscarinic receptors on their cell membrane and binding
to atropine may interfere with scleral remodeling.32 The
inhibitory effect of atropine is not likely executed through
an accommodative mechanism, because the inhibitory
effect of atropine on eye growth is also observed in chicks,
and these animals activate the ciliary muscle via nicotine
receptors rather than the muscarinic receptor.30
Taken our ﬁndings together with the existing literature,
we suggest the following guidelines for doctors treating
myopes at risk for high myopia in everyday clinical
practice: ﬁrst, identify and discuss the risk proﬁle of
the patient and provide lifestyle advice, such as increase
of the time spent outdoors. Second, start intervention
with atropine 0.5% and prescribe transitional multifocal
glasses. Third, perform regular follow up examinations
including visual acuity, reading acuity, cycloplegic
refraction, and axial length. Fourth, adjust treatment
regimen. In contrast, when SE and axial length have
remained stable for a period of 12 months, gradually
taper the atropine concentration to naught.
In conclusion, our study provides external validity
of ﬁndings from randomized controlled trials and shows
that atropine can be effective for progressive myopia
in daily clinical practice. Atropine should be considered
a treatment option in children at risk of high myopia
anywhere in the world.
Summary
What was known before
K Atropine is known to slow progressive myopia in Asians.
It is not widely used in Europe.
What this study adds
K Atropine eye drops can slow down eye growth in myopic
children of European descent, and is tolerated by the
majority of children. Intervention with atropine is a
treatment option in children with progressive myopia
irrespective of ethnicity.
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